X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (254) 254
Paper (185) 185
Publication (134) 134
Book / eBook (20) 20
Patent (12) 12
Magazine Article (2) 2
Book Chapter (1) 1
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
experiment (187) 187
particle physics (184) 184
physics (178) 178
high energy physics - experiment (170) 170
physics - high energy physics - experiment (163) 163
high energy physics (96) 96
[ phys.hexp ] physics [physics]/high energy physics - experiment [hep-ex] (81) 81
physical sciences (70) 70
fysik (69) 69
natural sciences (69) 69
naturvetenskap (69) 69
phenomenology (53) 53
particle physics - experiment (50) 50
nuclear experiment (48) 48
subatomär fysik (42) 42
physics of elementary particles and fields (41) 41
subatomic physics (41) 41
elementary particles, quantum field theory (35) 35
quantum field theories, string theory (35) 35
physics, particles & fields (30) 30
hadron-hadron scattering (24) 24
astrophysics (23) 23
high energy astrophysical phenomena (23) 23
collisions (22) 22
detectors (22) 22
index medicus (22) 22
science & technology (21) 21
ciências físicas [ciências naturais] (20) 20
física (20) 20
classical and quantum gravitation, relativity theory (19) 19
humans (19) 19
quantum physics (19) 19
astronomy, astrophysics and cosmology (18) 18
física nuclear (17) 17
female (16) 16
male (16) 16
measurement science and instrumentation (16) 16
nuclear energy (16) 16
nuclear physics, heavy ions, hadrons (16) 16
[phys.hexp]physics [physics]/high energy physics - experiment [hep-ex] (15) 15
analysis (15) 15
astronomy & astrophysics (15) 15
glioblastoma (15) 15
oncology (15) 15
luminosity (13) 13
middle aged (13) 13
standard model (13) 13
adult (12) 12
large hadron collider (12) 12
model (12) 12
decay (11) 11
lhc (11) 11
parton distributions (11) 11
tumors (11) 11
aged (10) 10
bevacizumab (10) 10
clinical neurology (10) 10
cross sections (10) 10
physics, nuclear (10) 10
engineering (9) 9
patients (9) 9
searching (9) 9
hadrons (8) 8
higgs bosons (8) 8
leptons (8) 8
particle accelerators (8) 8
physics and astronomy (8) 8
protons (8) 8
radiotherapy (8) 8
survival (8) 8
transverse momentum (8) 8
young adult (8) 8
bosons (7) 7
brain tumors (7) 7
cancer (7) 7
care and treatment (7) 7
detectors de radiació (7) 7
glioblastoma multiforme (7) 7
instrumentation and detectors (7) 7
medicine & public health (7) 7
nuclear and high energy physics (7) 7
particle collisions (7) 7
partícules (7) 7
pathology (7) 7
settore fis/01 - fisica sperimentale (7) 7
supersymmetry (7) 7
atlas (6) 6
biomarkers (6) 6
brain (6) 6
brain cancer (6) 6
brain neoplasms - drug therapy (6) 6
brain neoplasms - genetics (6) 6
brain neoplasms - mortality (6) 6
brain neoplasms - pathology (6) 6
elementary particles (6) 6
follow-up studies (6) 6
glioblastoma - drug therapy (6) 6
glioblastoma - mortality (6) 6
glioma (6) 6
gliomas (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, ISSN 1470-2045, 2014, Volume 15, Issue 10, pp. 1100 - 1108
Journal Article
by Weller, Michael and Butowski, Nicholas and Tran, David D and Recht, Lawrence and Recht, Lawrence D and Lim, Michael and Hirte, Hal and Ashby, Lynn and Mechtler, Laszlo and Goldlust, Samuel and Goldlust, Samuel A and Iwamoto, Fabio and Drappatz, Jan and O'Rourke, James and O'Rourke, Donald M and Wong, Mark and Hamilton, Mark G and Hamilton, Mark and Finocchiaro, Gaetano and Perry, James and Wick, Wolfgang and Green, Jennifer and He, Yi and Turner, Christopher D and Yellin, Michael J and Keler, Tibor and Davis, Thomas A and Stupp, Roger and Sampson, John H and Campian, Jian and Becker, Kevin and Barnett, Gene and Nicholas, Garth and Desjardins, Annick and Benkers, Tara and Wagle, Naveed and Groves, Morris and Kesari, Santosh and Horvath, Zsolt and Merrell, Ryan and Curry, Richard and Schuster, David and Mrugala, Maciej and Jensen, Randy and Trusheim, John and Lesser, Glenn and Belanger, Karl and Sloan, Andrew and Purow, Benjamin and Fink, Karen and Raizer, Jeffrey and Schulder, Michael and Nair, Suresh and Peak, Scott and Brandes, Alba and Mohile, Nimish and Landolfi, Joseph and Olson, Jon and Jennens, Ross and DeSouza, Paul and Robinson, Bridget and Crittenden, Marka and Shih, Kent and Flowers, Alexandra and Ong, Shirley and Connelly, Jennifer and Hadjipanayis, Costas and Giglio, Pierre and Mott, Frank and Mathieu, David and Lessard, Nathalie and Sepulveda, Sanchez Juan and Lövey, József and Wheeler, Helen and Inglis, Po-Ling and Hardie, Claire and Bota, Daniela and Lesniak, Maciej and Portnow, Jana and Frankel, Bruce and Junck, Larry and Thompson, Reid and Berk, Lawrence and McGhie, John and Macdonald, David and Saran, Frank and Soffietti, Riccardo and Blumenthal, Deborah and André de, Sá Barreto Costa Marcos and Nowak, Anna and Singhal, Nimit and Hottinger, Andreas and Schmid, Andrea and Srkalovic, Gordan and Baskin, David and Fadul, Camilo and Nabors, Louis and LaRocca, Renato and Villano, John and Paleologos, Nina and ... and ACT IV Trial Investigators and ACT IV trial investigators
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1373 - 1385
Rindopepimut (also known as CDX-110), a vaccine targeting the deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet... 
GLIOMAS | ONCOLOGY | RECURSIVE PARTITIONING ANALYSIS | GROWTH-FACTOR | RADIOTHERAPY | CANCER | PEPTIDE | ADJUVANT TEMOZOLOMIDE | Dacarbazine - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Brain Neoplasms - pathology | ErbB Receptors - genetics | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Dose-Response Relationship, Drug | Young Adult | Glioblastoma - genetics | Time Factors | Dacarbazine - analogs & derivatives | Adult | Female | Vaccines, Subunit - adverse effects | Brain Neoplasms - mortality | Dacarbazine - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cancer Vaccines - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Brain Neoplasms - genetics | Cancer Vaccines - adverse effects | Treatment Outcome | Brain Neoplasms - drug therapy | Disease-Free Survival | Internationality | Vaccines, Subunit - administration & dosage | Glioblastoma - pathology | Survival Analysis | Aged | Temozolomide | Glioblastoma - drug therapy | Glioblastoma - mortality | Antimitotic agents | Clinical trials | Care and treatment | Product development | Antineoplastic agents | Glioblastoma multiforme | Analysis
Journal Article
The Lancet, ISSN 0140-6736, 02/2019, Volume 393, Issue 10172, pp. 678 - 688
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 01/2016, Volume 8, Issue 1, pp. 39 - 57
Glioblastoma multiforme (GBM) is treated by surgical resection followed by radiochemotherapy. Bevacizumab is commonly deployed for anti‐angiogenic therapy of... 
macrophage polarization | anti‐angiogenic therapy | glioblastoma | tumor angiogenesis | therapy resistance | Tumor angiogenesis | Anti-angiogenic therapy | Therapy resistance | Macrophage polarization | Glioblastoma | MEDICINE, RESEARCH & EXPERIMENTAL | anti-angiogenic therapy | NEWLY-DIAGNOSED GLIOBLASTOMA | OVARIAN-CANCER | SERUM ANGIOPOIETIN-2 | ANTIANGIOGENIC THERAPY | COLORECTAL-CANCER | TIE2-EXPRESSING MONOCYTES | POTENT ANTITUMOR | TUMOR-ASSOCIATED MACROPHAGES | DISEASE PROGRESSION | Mannose-Binding Lectins - metabolism | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - pharmacology | Humans | Receptors, Vascular Endothelial Growth Factor - pharmacology | Recombinant Fusion Proteins - therapeutic use | Brain Neoplasms - pathology | Drug Resistance, Neoplasm | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Angiopoietin-2 - metabolism | Brain - metabolism | Lectins, C-Type - metabolism | Neoplasm Grading | Female | Brain Neoplasms - mortality | Macrophages - immunology | Angiopoietin-2 - blood | Disease Models, Animal | Endothelial Cells - metabolism | Mice, Inbred C57BL | Receptors, Cell Surface - metabolism | Mice, Transgenic | Macrophages - cytology | Brain Neoplasms - drug therapy | Up-Regulation - drug effects | Macrophages - metabolism | Animals | Signal Transduction - drug effects | Endothelial Cells - cytology | Glioblastoma - pathology | Brain - pathology | Mice | Angiopoietin-2 - antagonists & inhibitors | Glioblastoma - drug therapy | Glioblastoma - mortality | Analysis | Permeability | Angiogenesis inhibitors | T cells | Vascular endothelial growth factor | Health aspects | Glioblastoma multiforme | Endothelium | Cell survival | Angiopoietin | Therapeutic applications | Brain cancer | Lymphocytes T | Macrophages | Cancer therapies | Investigations | Endothelial cells | Bevacizumab | Angiogenesis | Genotype & phenotype | Brain research | Rodents | Growth factors | Tumors | Neuroscience | Pharmacology & Drug Discovery | Cancer
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e13524 - e13524
Journal Article
International Journal of Molecular Sciences, ISSN 1661-6596, 05/2017, Volume 18, Issue 5, p. 995
Galunisertib, a Transforming growth factor-beta RI (TGF-beta RI) kinase inhibitor, blocks TGF-beta-mediated tumor growth in glioblastoma. In a three-arm study... 
Biomarkers | pSMAD2 | TGF-β | Galunisertib monohydrate (LY2157299) | CDK4/CDK6 | SURVIVAL | IMMUNE CELLS | biomarkers | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-II | CANCER | CHEMISTRY, MULTIDISCIPLINARY | TUMOR-INFILTRATING LYMPHOCYTES | TGF-beta | galunisertib monohydrate (LY2157299) | RADIOTHERAPY | Pyrazoles - therapeutic use | Humans | Lomustine - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | Quinolines - administration & dosage | Neoplasm Recurrence, Local - pathology | CD4-CD8 Ratio | Forkhead Transcription Factors - metabolism | Biomarkers, Tumor - metabolism | Adult | Female | Lomustine - therapeutic use | Neoplasm Recurrence, Local - blood | Cytokines - blood | Pyrazoles - adverse effects | Glioblastoma - blood | Smad2 Protein - metabolism | Antineoplastic Combined Chemotherapy Protocols | Biomarkers, Tumor - blood | Pyrazoles - administration & dosage | Forkhead Transcription Factors - blood | Glioblastoma - pathology | Survival Analysis | Isocitrate Dehydrogenase - metabolism | Quinolines - therapeutic use | Glioblastoma - drug therapy | Lomustine - administration & dosage | Quinolines - adverse effects | Therapy | CD8 antigen | Glioblastoma | Transforming growth factor-a | Lymphocytes T | Dehydrogenase | Kinases | Macrophages | CCL22 protein | Alterations | Macrophage-derived chemokine | Histopathology | Lymphocytes | Foxp3 protein | Isocitrate dehydrogenase | Dosing | Leukocytes (eosinophilic) | Glial fibrillary acidic protein | Markers | Pharmacology | CD3 antigen | Assessments | Patients | Survival | CD4 antigen | Pathology | Inhibitors | Chemokines | Cytoplasm | Plasmas (physics) | Eosinophils | Tumors
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 18_suppl, pp. LBA2000 - LBA2000
LBA2000 Background: In patients with MGMT-nonmethylated glioblastoma (GBM), primary chemotherapy with temozolomide (TMZ) is at best moderately effective. There... 
Journal Article